title: Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
abstract: BACKGROUND
  Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investigate the anticancer efficacy and mechanism of combined sorafenib and 5-FU therapy in vitro in HCC cell lines MHCC97H and SMMC-7721.
  
  
  METHODS
  Drug effects on cell proliferation were evaluated by cell viability assays. Combined-effects analyses were conducted according to the median-effect principle. Cell cycle distribution was measured by flow cytometry. Expression levels of proteins related to the RAF/MEK/ERK and STAT3 pathways and to cell cycle progression (cyclin D1) were determined by western blot analysis.
  
  
  RESULTS
  Sorafenib and 5-FU alone or in combination showed significant efficacy in inhibiting cell proliferation in both cell lines tested. However, a schedule-dependent combined effect, associated with the order of compound treatments, was observed. Efficacy was synergistic with 5-FU pretreatment followed by sorafenib, but it was antagonistic with the reverse treatment order. Sorafenib pretreatment resulted in a significant increase in the half inhibitory concentration (IC50) of 5-FU in both cell lines. Sorafenib induced G1-phase arrest and significantly decreased the proportion of cells in S phase when administrated alone or followed by 5-FU. The RAF/MEK/ERK and STAT3 pathways were blocked and cyclin D1 expression was down regulated significantly in both cell lines by sorafenib; whereas, the kinase pathways were hardly affected by 5-FU, and cyclin D1 expression was up regulated.
  
  
  CONCLUSIONS
  Antitumor activity of sorafenib and 5-FU, alone or in combination, is seen in HCC cell lines. The nature of the combined effects, however, depends on the particular cell line and treatment order of the two compounds. Sorafenib appears to reduce sensitivity to 5-FU through down regulation of cyclin D1 expression by inhibiting RAF/MEK/ERK and STAT3 signaling, resulting in G1-phase arrest and reduction of the S-phase cell subpopulation when 5-FU is administrated after sorafenib, in which situation, combination treatment of the two agents results in antagonism; on the other hand, when sorafenib is administrated afterward, it can continue to work since it is not cell cycle specific, as a result, combination treatment of the two agents shows an additive-to-synergistic effect.
authors.affiliation: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
authors.forename: Lifen
authors.initials: L
authors.lastname: Deng
authors.forename: Zhenggang
authors.initials: Z
authors.lastname: Ren
authors.forename: Qingan
authors.initials: Q
authors.lastname: Jia
authors.forename: Weizhong
authors.initials: W
authors.lastname: Wu
authors.forename: Hujia
authors.initials: H
authors.lastname: Shen
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004357:Drug Synergism; D005434:Flow Cytometry; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage; D015398:Signal Transduction / Q000187:drug effects*; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D005472:Fluorouracil
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Lancet. 2012 Mar 31;379(9822):1245-55
references.pmid: 22353262
references.citation: Curr Opin Cell Biol. 2003 Apr;15(2):158-63
references.pmid: 12648671
references.citation: Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
references.pmid: 17126425
references.citation: Oncogene. 2000 May 15;19(21):2474-88
references.pmid: 10851046
references.citation: Anticancer Drugs. 2011 Jan;22(1):79-88
references.pmid: 20881478
references.citation: Cancer Treat Rev. 2011 May;37(3):212-20
references.pmid: 20724077
references.citation: Int J Oncol. 2004 Dec;25(6):1839-47
references.pmid: 15547725
references.citation: Mol Cancer Ther. 2008 Nov;7(11):3519-26
references.pmid: 19001435
references.citation: FEBS J. 2010 Jan;277(1):2-21
references.pmid: 19843174
references.citation: Pharmacol Rev. 2006 Sep;58(3):621-81
references.pmid: 16968952
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6771-90
references.pmid: 16170185
references.citation: Oncol Lett. 2012 Jun;3(6):1195-1202
references.pmid: 22783417
references.citation: J Cancer Res Clin Oncol. 2005 Jun;131(6):385-94
references.pmid: 15754201
references.citation: Int J Colorectal Dis. 2013 Mar;28(3):385-98
references.pmid: 22983756
references.citation: World J Gastroenterol. 2012 Jul 14;18(26):3426-34
references.pmid: 22807613
references.citation: Cancer Res. 2006 Dec 15;66(24):11851-8
references.pmid: 17178882
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5189-99
references.pmid: 20884624
references.citation: Nat Rev Cancer. 2009 Nov;9(11):798-809
references.pmid: 19851315
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Cancer Chemother Pharmacol. 2012 Mar;69(3):773-80
references.pmid: 22033636
references.citation: FEBS J. 2011 Sep;278(18):3494-507
references.pmid: 21790999
references.citation: Mol Cancer. 2007 Apr 02;6:24
references.pmid: 17407548
references.citation: Mol Cancer Ther. 2010 Apr;9(4):953-62
references.pmid: 20371721
references.citation: Cancer Res. 2007 Oct 1;67(19):9443-54
references.pmid: 17909054
references.citation: J Gastroenterol Hepatol. 2012 Dec;27(12):1850-7
references.pmid: 23020312
references.citation: Hepatology. 2009 Dec;50(6):1861-70
references.pmid: 19821497
references.citation: BMC Med. 2009 Aug 24;7:41
references.pmid: 19698189
references.citation: World J Gastroenterol. 2011 Sep 14;17(34):3922-32
references.pmid: 22025881
references.citation: J Hepatol. 2011 Nov;55(5):1041-8
references.pmid: 21354226
references.citation: Nat Rev Cancer. 2004 Feb;4(2):97-105
references.pmid: 14964307
references.citation: Mol Biol Rep. 2012 Feb;39(2):1683-9
references.pmid: 21617941
references.citation: Oral Oncol. 2009 Feb;45(2):109-15
references.pmid: 18710819
references.citation: Mol Cancer Ther. 2010 Mar;9(3):742-50
references.pmid: 20197401
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206